Sign Out
Pregnancy: There is no information on the use of irinotecan in pregnant women. Irinotecan has been shown to be embryotoxic, foetotoxic and teratogenic in rabbits and rats. Therefore, Irinotesin must not be used during pregnancy (see Contraindications and Precautions).
Women of child-bearing potential: Women of child-bearing age receiving Irinotesin should be advised to avoid becoming pregnant, and to inform the treating physician immediately should this occur (see Contraindications and Precautions).
Contraceptive measures must be taken by women of child-bearing age, and also by male patients, during and for at least three months after cessation of therapy.
Lactation: In lactating rats, 14C-irinotecan was detected in milk. It is not known whether irinotecan is excreted in human milk. Consequently, because of the potential for adverse reactions in nursing infants, breast feeding must be discontinued for the duration of irinotecan therapy (see Contraindications).
